BRYOSTATIN 1 + VINCRISTINE IN NON-HODGKIN'S LYMPHOMA POST TRANSPLANT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this study are: 1) to evaluate the response rate when bryostatin 1 is given in combination with vincristine in patients with low and intermediate grade non-Hodgkin's lymphoma who have progressed or relapsed following an autologous bone marrow or stem cell transplant, 2) to determine if blunting of apoptotic response at 6 hours of treatment using annexin V staining of peripheral blood CD5+ and CD19+ lymphocytes by flow cytometry is predictive of outcome (i.e. lack of clinical response), and 3) to prospectively evaluate the incidence of greater than or equal to grade 3 myelotoxicity with this regimen. Subjects will receive bryostatin-1 by vein continuously over 24 hours followed by vincristine given by vein over 5 minutes. This treatment will be repeated every two weeks. Two 2-week treatment periods make up one cycle (28 days). Subjects may receive up to six cycles of therapy. If responsive, patient may then switch to a treatment once every 3 weeks and continue on therapy unless there is disease progression or a lack of response. Subjects will stay at the GCRC only on Cycle 1, Day 1 for medication administration and blood draws at 0, 6, 24 and 30 hours. The study will enroll approximately 28 subjects at four sites (about 15 subjects at this site).